Efficacy, safety, tolerability, and immunogenicity of inactivated hepatitis A vaccine (VAQTA™) in initially seronegative healthy children and adolescents 2–16 years of age

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Hepatitis A vaccine inactivated (Primary)
Indications Hepatitis A
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

28 Apr 2021 Status changed from not stated to completed.
28 Apr 2021 New trial record
15 Apr 2021 The protocol was amended to evaluate the persistence of hepatitis A antibody 2.5-3.5 through ~10 years post-vaccination.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com